Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong.
Cancer Lett. 2021 Jun 28;508:30-46. doi: 10.1016/j.canlet.2021.02.012. Epub 2021 Mar 20.
There are minimal data regarding the prevalence of cancer in patients with coronavirus disease 2019 (COVID-19), as well as the incidence of severe illness and rate of mortality in COVID-19 patients with cancer. PubMed, Embase, Cochrane Library, and Web of Science were systematically searched, from database inception to July 15, 2020, for studies of patients with COVID-19 that included information regarding comorbid cancer. In total, 109 eligible global studies were included in this systematic review. Ninety studies with 94,845 COVID-19 patients, among which 4106 exhibited comorbid cancer, were included in the meta-analysis regarding prevalence of comorbid cancer. Twenty-three studies with 71,969 COVID-19 patients, among which 4351 with comorbid cancer had severe illness or death, were included in the meta-analysis. The overall prevalence of cancer among COVID-19 patients was 0.07 (95% CI 0.05-0.09). The cancer prevalence in COVID-19 patients was higher in Europe (0.22, 95% CI 0.17-0.28) than in the Asia-Pacific region (0.04, 95% CI 0.03-0.06) or North America (0.05, 95% CI 0.04-0.06). The cancer prevalence in COVID-19 patients aged >60 years was 0.10 (95% CI 0.07-0.14), while the prevalence among patients aged ≤60 years was 0.05 (95% CI 0.03-0.06). The pooled prevalence of severe illness among COVID-19 patients with cancer was 0.34 (95% CI 0.26-0.42) and the pooled mortality rate of COVID-19 patients with cancer was 0.20 (95% CI 0.16-0.25). Pooled incidences of severe illness among COVID-19 patients with cancer from Asia Pacific, Europe, and North America were 0.38 (95% CI 0.24-0.52), 0.39 (95% CI 0.25-0.53), and 0.26 (95% CI 0.20-0.31), respectively; pooled mortality rates from the Asia-Pacific region, Europe, and North America were 0.17 (95% CI 0.10-0.24), 0.26 (95% CI 0.18-0.35), and 0.19 (95% CI 0.13-0.25), respectively.
关于 2019 年冠状病毒病（COVID-19）患者的癌症患病率，以及癌症患者 COVID-19 严重程度和死亡率的发生率，数据很少。从数据库开始到 2020 年 7 月 15 日，系统地检索了 PubMed、Embase、Cochrane 图书馆和 Web of Science，以查找包含 COVID-19 合并癌症信息的 COVID-19 患者研究。这项系统评价共纳入了 109 项来自全球的合格研究。90 项研究纳入了 94845 例 COVID-19 患者，其中 4106 例患有合并癌症，用于分析合并癌症的患病率。23 项研究纳入了 71969 例 COVID-19 患者，其中 4351 例患有合并癌症，发生严重疾病或死亡，用于分析严重疾病或死亡率。COVID-19 患者的癌症总患病率为 0.07（95%CI 0.05-0.09）。COVID-19 患者的癌症患病率在欧洲（0.22，95%CI 0.17-0.28）高于亚太地区（0.04，95%CI 0.03-0.06）或北美（0.05，95%CI 0.04-0.06）。COVID-19 患者中≥60 岁患者的癌症患病率为 0.10（95%CI 0.07-0.14），而≤60 岁患者的癌症患病率为 0.05（95%CI 0.03-0.06）。COVID-19 合并癌症患者严重疾病的合并患病率为 0.34（95%CI 0.26-0.42），COVID-19 合并癌症患者的死亡率为 0.20（95%CI 0.16-0.25）。来自亚太、欧洲和北美的 COVID-19 合并癌症患者严重疾病的合并发生率分别为 0.38（95%CI 0.24-0.52）、0.39（95%CI 0.25-0.53）和 0.26（95%CI 0.20-0.31）；来自亚太地区、欧洲和北美的 COVID-19 合并癌症患者的死亡率分别为 0.17（95%CI 0.10-0.24）、0.26（95%CI 0.18-0.35）和 0.19（95%CI 0.13-0.25）。
